ANDA Postapproval Changes: Best Practices and Strategies to Avoid Common Quality Assessment Issues

แชร์
ฝัง
  • เผยแพร่เมื่อ 13 พ.ค. 2021
  • Niles Ron, PhD, MBA, Branch Chief for the Division of Post-Marketing Activities II, discusses common post-marketing quality assessment issues, strategies to avoid them, and best practices.
    Learn more at: www.fda.gov/drugs/news-events...
    -------------------- 
    FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

    Upcoming Training - www.fda.gov/cdersbia
    SBIA Listserv - public.govdelivery.com/accoun...
    SBIA 2021 Playlist - • 2021 CDER Small Busine...
    SBIA LinkedIn: / cder-small-business-an...
    SBIA Training Resources - www.fda.gov/cdersbialearn
    Twitter - / fda_drug_info
    Email - CDERSBIA@fda.hhs.gov  
    Phone - (301) 796-6707 I (866) 405-5367

ความคิดเห็น •